Literature DB >> 25696746

A guideline for uniform and optimal atherosclerotic risk factor assessment across clinical specialities in a large hospital.

S M Boekholdt, R J G Peters.   

Abstract

Solid evidence is available concerning the beneficial effect of atherosclerotic risk factor management both in primary and secondary prevention. However, recent registries have indicated considerable potential for improvement of clinical practice concerning secondary prevention of atherosclerosis. The guideline 'Secondary Prevention of Atherosclerosis' is aimed at the improvement and standardisation of atherosclerotic risk factor assessment in cardiovascular patients hospitalised at the Academic Medical Centre in Amsterdam. The guideline was developed by a task force, consisting of physicians from the Departments of Cardiology, Cardiothoracic Surgery, Internal Medicine, Interventional Radiology, Neurology, Pharmacology and Vascular Surgery. The guideline offers a standardised method for the identification of atherosclerotic risk factors and provides thresholds for treatment, treatment goals and the treatment of choice. A form listing all relevant data is completed before discharge and is mailed with the discharge letter to the referring physician and to the general practitioner.

Entities:  

Keywords:  atherosclerosis; guideline; risk factors; secondary prevention

Year:  2001        PMID: 25696746      PMCID: PMC2504424     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  15 in total

Review 1.  Secondary stroke prevention: A European perspective.

Authors:  G Devuyst; M Paciaroni; J Bogousslavsky
Journal:  Cerebrovasc Dis       Date:  1999       Impact factor: 2.762

2.  Changes in plasma cholesterol levels after hospitalization for acute coronary events.

Authors:  R Brugada; N K Wenger; T A Jacobson; W S Clark; G Cotsonis; A Iglesias
Journal:  Cardiology       Date:  1996 May-Jun       Impact factor: 1.869

3.  Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.

Authors:  R P Byington; B R Davis; J F Plehn; H D White; J Baker; S M Cobbe; J Shepherd
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

4.  Clinical utility of lipid and lipoprotein levels during hospitalization for acute myocardial infarction.

Authors:  J M Gaziano; C H Hennekens; S Satterfield; C Roy; H D Sesso; J L Breslow; J E Buring
Journal:  Vasc Med       Date:  1999       Impact factor: 3.239

Review 5.  Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease.

Authors:  G Assmann; P Cullen; F Jossa; B Lewis; M Mancini
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-08       Impact factor: 8.311

6.  Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

Authors:  G C Fonarow; W J French; L S Parsons; H Sun; J A Malmgren
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

7.  Current therapies for secondary prevention after myocardial infarction.

Authors:  C E Cannon; S C Smith
Journal:  Curr Opin Cardiol       Date:  1999-03       Impact factor: 2.161

8.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.

Authors:  J Shepherd; G J Blauw; M B Murphy; S M Cobbe; E L Bollen; B M Buckley; I Ford; J W Jukema; M Hyland; A Gaw; A M Lagaay; I J Perry; P W Macfarlane; A E Meinders; B J Sweeney; C J Packard; R G Westendorp; C Twomey; D J Stott
Journal:  Am J Cardiol       Date:  1999-11-15       Impact factor: 2.778

9.  Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation.

Authors:  A Undas; K E Brummel; J Musial; K G Mann; A Szczeklik
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

10.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.